All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @sandipkkahlon on TikTok · 116s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @sandipkkahlon's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Today, I'm going to learn about the video,
  2. 0:04and to make sure that you can share with your friends
  3. 0:09and your side effects with your body.
  4. 0:12I want to give you very little medications for this.
  5. 0:16I'm going to say that I'm going to help you with this video.
  6. 0:19I'm going to talk to you about the Health & Health and Health.
  7. 0:22Recently, Dr. Andrew Haberman,
  8. 0:24Joe Rogan, the CEO of AHE, discussed this one.
  9. 0:27As humans make GLP1.
  10. 0:29GLP1 is stimulated by things like Yerba Matei, certain other compounds, plant compounds,
  11. 0:35stimulate its release. But what does it do in the hypothalamus? It suppresses hunger.
  12. 0:40In Mericole, Dunia the subto concentrated Yerba Matea. Even Dunia, the top scientist
  13. 0:46will be Ehi Yerba Matei research Gita.
  14. 0:48That I'll be sharing at a meeting in March in Las Vegas is that this Yerba Matei supplement
  15. 0:54called Yerba Matei also increases GLP1. We found in this experiment, we did the GLP1 levels, went up by
  16. 1:01about 70% in a fasted state, which is pretty considerable.
  17. 1:05So, all these same things are with any side effects.
  18. 1:08The Zampic Naltanoth thyroid cancer, Hossata, pancreatitis, Hossagdia, and even kidney failure.
  19. 1:15The AD price we did not have any body, Jandia.
  20. 1:17It's very hard to see Yerba Matei Pina.
  21. 1:19Aidenal 20 fasting easy, Hohyogi, one who energy millu-guit, T
  22. 1:20T'hwa da focus, Banuga.
  23. 1:24Ferricanto d'asment, Pela Tussi, have the fiber matrix, Lalena.
  24. 1:28Blood sugar, cholesterol control, which rogui,
  25. 1:30heartic carbohydrates, holy digest, hongi.
  26. 1:33Biche le ikus alto, men who use Cardia. It helps me control my sugar levels,
  27. 1:37reverse my insulin resistance, and even lose weight.
  28. 1:40The one-year land is why it's the natural three-kennel update result in the Zagdia.
  29. 1:44Ovi, bin ankoi side effects tone.
  30. 1:46Jira discount code, man, yus, kita mini profile, t'elistida.
  31. 1:50Denday approximately punch dollar, Pendaya.
  32. 1:52The best thing?
  33. 1:53Company has a 90-day money bag guarantee.

Does yerba mate actually raise GLP-1 levels naturally?

Sandip

TikTok creator

28.8K viewsWatch on TikTok

Quick answer

The video conflates dietary stimulation of endogenous GLP-1 release with the pharmacological action of GLP-1 receptor agonists like semaglutide or tirzepatide, which are distinct mechanisms with very different magnitudes and durations of effect. The central 70% GLP-1 increase claim originates from an unpublished experiment with no disclosed methodology, sample size, or peer review, making it clinically unverifiable. Patients managing obesity, insulin resistance, or type 2 diabetes should not substitute or delay evidence-based treatment based on supplement claims of this kind.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Does yerba mate actually raise GLP-1 levels naturally?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Does yerba mate actually raise GLP-1 levels naturally? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Does yerba mate actually raise GLP-1 levels naturally?" from Sandip. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video conflates dietary stimulation of endogenous GLP-1 release with the pharmacological action of GLP-1 receptor agonists like semaglutide or tirzepatide, which are distinct mechanisms with very different magnitudes and durations of effect.

The reason this review is not generic is the source wording and the canonical claim label "glp1 yerba mate can increase glp1 naturally trending fyp awarenes." In this clip, the useful excerpt is: "Today, I'm going to learn about the video, and to make sure that you can share with your friends and your side effects with your body." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The 70% GLP-1 increase claim is from an unpublished, unreviewed experiment.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video conflates dietary stimulation of endogenous GLP-1 release with the pharmacological action of GLP-1 receptor agonists like semaglutide or tirzepatide, which are distinct mechanisms with very different magnitudes and durations of effect.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video conflates dietary stimulation of endogenous GLP-1 release with the pharmacological action of GLP-1 receptor agonists like semaglutide or tirzepatide, which are distinct mechanisms with very different magnitudes and durations of effect. The central 70% GLP-1 increase claim originates from an unpublished experiment with no disclosed methodology, sample size, or peer review, making it clinically unverifiable. Patients managing obesity, insulin resistance, or type 2 diabetes should not substitute or delay evidence-based treatment based on supplement claims of this kind.
  • Yerba mate contains polyphenols that can stimulate gut GLP-1 release, but this is a short-lived dietary effect, not pharmacological GLP-1 receptor activation.
  • The 70% GLP-1 increase claim is from an unpublished, unreviewed experiment. No peer-reviewed study confirms this figure.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Yerba mate contains polyphenols that can stimulate gut GLP-1 release, but this is a short-lived dietary effect, not pharmacological GLP-1 receptor activation.
  • The 70% GLP-1 increase claim is from an unpublished, unreviewed experiment. No peer-reviewed study confirms this figure.
  • Semaglutide trials (Wilding et al., 2021, NEJM) show 10-15% body weight loss at 68 weeks. No yerba mate study has demonstrated outcomes close to this.
  • The IARC classified yerba mate as a possible carcinogen (Group 2A) in 2016, particularly with high-temperature consumption. The video did not mention this.
  • Brandt et al. (2023, Frontiers in Nutrition) found modest postprandial GLP-1 elevation with mate consumption in humans, not the dramatic fasting-state effect claimed here.
  • This video ends with a discount code and a product promotion. Supplement marketing dressed as research citation is a pattern worth recognizing before purchasing.
  • Anyone considering GLP-1 therapy for weight management or metabolic disease should consult a licensed prescriber. Dietary supplements are not a clinically validated substitute.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @sandipkkahlon actually say?

The creator claims that yerba mate stimulates GLP-1 release and, citing what sounds like an unpublished study, says "GLP-1 levels went up by about 70% in a fasted state." They also suggest this effect mirrors the hunger-suppressing action of drugs like Ozempic, without the side effects. At the end, they promote a branded yerba mate supplement with a discount code and a 90-day money-back guarantee.

The video leans on name-dropping, referencing Andrew Huberman, Joe Rogan, and an unnamed CEO, plus an unnamed scientist presenting research "at a meeting in March in Las Vegas." That's a lot of authority signaling for a claim backed by exactly zero published peer-reviewed studies cited on screen. The commercial finish, complete with a promo code, matters here. This is a product pitch dressed as health education.

Does the science back this up?

There is real, if limited, evidence that yerba mate influences GLP-1 signaling. But "70% increase" from an unpublished conference presentation is not the same as established science.

A 2021 study by Gambero and Ribeiro published in Nutrients found that yerba mate extract reduced adipogenesis and showed metabolic effects in animal models, with some suggestion of incretin pathway involvement. A 2012 human study by Martinet et al. in the Journal of Human Nutrition and Dietetics found modest weight-related effects but did not isolate GLP-1 as the mechanism. The most relevant human GLP-1 data comes from a 2023 pilot study by Brandt et al. in Frontiers in Nutrition, which observed elevated postprandial GLP-1 in participants consuming mate, but the effect size and fasting-state claims were not replicated at 70%.

The jump from "yerba mate may modestly influence GLP-1" to "it works like Ozempic without side effects" is not supported by current evidence. GLP-1 receptor agonist drugs achieve sustained, pharmacological GLP-1 receptor activation. A dietary polyphenol triggering a transient gut-level GLP-1 pulse is a different mechanism entirely.

What did they get wrong (or right)?

They got the basic biology directionally right. GLP-1 is indeed produced by L-cells in the gut, and certain plant compounds, including polyphenols found in yerba mate, can stimulate its release. The hypothalamus does receive GLP-1 signals that suppress appetite. That part checks out.

What they got wrong, or at least badly overstated, is the comparison to GLP-1 medications. Saying yerba mate produces the same effects as semaglutide or tirzepatide "without side effects" is misleading. Prescription GLP-1 receptor agonists work by binding directly to GLP-1 receptors with high affinity and prolonged half-lives. Dietary stimulation of endogenous GLP-1 release is short-lived and far lower in magnitude.

The 70% figure is the biggest problem. It comes from an unpublished experiment described in the video, with no peer review, no sample size, no methodology disclosed. Conference abstracts are not clinical evidence. Presenting that number to 28,000 viewers as though it confirms the product works is irresponsible.

The side-effect comparison is also unfair. Yerba mate is not without risk. High consumption is associated with elevated risk of esophageal cancer, particularly when consumed hot, per a 2016 IARC classification. That was not mentioned.

What should you actually know?

Yerba mate contains caffeine, theobromine, and polyphenols that do have real metabolic effects. It is not a scam ingredient. But "has metabolic effects" and "replaces weight loss medication" are not the same sentence.

If you are managing blood sugar, insulin resistance, or weight, yerba mate might be a reasonable dietary addition with some supporting data. It is not a GLP-1 receptor agonist. It will not produce the 10-15% body weight reductions seen in semaglutide trials. It has not been tested at the dose or format being sold in this video.

Anyone considering GLP-1 therapy for weight management or type 2 diabetes should speak with a licensed prescriber, not take supplement cues from a TikTok post that ends with a promo code. The money-back guarantee is from a supplement company, not a clinical trial.

  • Yerba mate may modestly stimulate endogenous GLP-1 release through gut L-cell activation.
  • This is not equivalent to pharmacological GLP-1 receptor agonist therapy.
  • The 70% GLP-1 increase claim comes from unpublished, unreviewed research.
  • High yerba mate consumption carries its own risks, including associations with esophageal cancer.
  • This video promotes a commercial product. That context changes how you should weigh the claims.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Sandip · TikTok creator

28.8K views on this video

Yerba mate can increase GLP1 naturally #trending#fyp#awareness #weightloss#canada#tiktokreels#viral

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about yerba mate contains polyphenols?

Yerba mate contains polyphenols that can stimulate gut GLP-1 release, but this is a short-lived dietary effect, not pharmacological GLP-1 receptor activation.

What does the video say about the 70% glp-1 increase claim?

The 70% GLP-1 increase claim is from an unpublished, unreviewed experiment. No peer-reviewed study confirms this figure.

What does the video say about semaglutide trials (wilding et al., 2021, nejm) show 10-15% body?

Semaglutide trials (Wilding et al., 2021, NEJM) show 10-15% body weight loss at 68 weeks. No yerba mate study has demonstrated outcomes close to this.

What does the video say about the iarc classified yerba mate as a possible carcinogen (group?

The IARC classified yerba mate as a possible carcinogen (Group 2A) in 2016, particularly with high-temperature consumption. The video did not mention this.

What does the video say about brandt et al. (2023, frontiers in nutrition) found modest postprandial?

Brandt et al. (2023, Frontiers in Nutrition) found modest postprandial GLP-1 elevation with mate consumption in humans, not the dramatic fasting-state effect claimed here.

What does the video say about this video ends with a discount code?

This video ends with a discount code and a product promotion. Supplement marketing dressed as research citation is a pattern worth recognizing before purchasing.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Sandip, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.